

## **AngioDynamics to Launch Tip Location System in Canada**

### **Celerity System to be Showcased at AVA 2013**

ALBANY, N.Y., Sept. 18, 2013 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced its distribution partner, Medcomp Inc., has received Health Canada approval for the Celerity tip location system. AngioDynamics plans to initiate distribution of the Celerity system in Canada in October 2013 and will showcase the technology at the Association for Vascular Access' (AVA) Annual Scientific Meeting taking place Sept. 20-23, 2013 in Nashville, Tenn.

"The ability to offer an integrated tip location system puts us in a very strong competitive position," said Chuck Greiner, Senior Vice President of AngioDynamics' Global Vascular Access Franchise. "We believe the combination of the Celerity system with our market-leading, thrombus-resistant BioFlo technology may provide unparalleled clinical and economic advantages, and has the potential to become the gold standard in the PICC market."

The Celerity tip location system is an ECG-based peripherally inserted central catheter (PICC) tip confirmation technology indicated for use as an alternative to chest x-ray and fluoroscopy for PICC tip placement in adult patients. The system has been approved for commercial sale by Health Canada and is currently under regulatory review in the United States and in Europe.

In January, AngioDynamics entered into a non-exclusive, global distribution agreement with Medcomp for the Celerity tip location system. The Company plans to highlight the technology at AVA 2013, where it will be exhibiting at booth 517.

### **About AngioDynamics**

AngioDynamics Inc. is a leading provider of innovative, minimally invasive medical devices used by professional healthcare providers for vascular access, surgery, peripheral vascular disease and oncology. AngioDynamics' diverse product lines include market-leading ablation systems, fluid management systems, vascular access products, angiographic products and accessories, angioplasty products, drainage products, thrombolytic products and venous products. More information is available at [www.AngioDynamics.com](http://www.AngioDynamics.com).

### **Trademarks**

AngioDynamics, the AngioDynamics logo and BioFlo are trademarks and/or registered trademarks of AngioDynamics Inc., an affiliate or a subsidiary. Celerity is a trademark and/or registered trademark of Medcomp Inc.

### **Safe Harbor**

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics' expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include the words such as "expects," "reaffirms," "intends," "anticipates," "plans," "believes," "seeks," "estimates," "optimistic," or variations of such words and similar expressions, are forward-looking statements. These forward looking statements are not guarantees of future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ from AngioDynamics' expectations. Factors that may affect the actual results achieved by AngioDynamics include, without limitation, the ability of AngioDynamics to develop its existing and new products, technological advances and patents attained by competitors, future actions by the FDA or other regulatory agencies, domestic and foreign health care reforms and government regulations, results of pending or future clinical trials, overall economic conditions, the results of on-going litigation, the effects of economic, credit and capital market conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, the ability of AngioDynamics to integrate purchased businesses, including Navilyst Medical and its products, R&D capabilities, infrastructure and employees as well as the risk factors listed from time to time in AngioDynamics' SEC filings, including but not limited to its Annual Report on Form 10-K for the year ended May 31, 2013. AngioDynamics does not assume any obligation to publicly update or revise any forward-looking statements for any reason.

AngioDynamics, Inc.

Mark Frost, CFO

(800) 772-6446 x1981

[mfrost@AngioDynamics.com](mailto:mfrost@AngioDynamics.com)

Investor Relations Contacts:

EVC Group, Inc.

Michael Polyviou/Robert Jones

(212) 850-6020; (646) 201-5447

[mpolyviou@evcgroup.com](mailto:mpolyviou@evcgroup.com); [bjones@evcgroup.com](mailto:bjones@evcgroup.com)

Media Contact:

EVC Group, Inc.

John Carter

(212) 850-6021

[jcarter@evcgroup.com](mailto:jcarter@evcgroup.com)

Source: AngioDynamics

News Provided by Acquire Media